What's Behind The Success Of Korean Biosimilars?
Executive Summary
Celltrion and Samsung Bioepis are moving fast to grab leading positions in the global biosimilars space, but how have these two firms got to where there are now? Scrip takes a look at what is driving their success and where they are heading next.
You may also be interested in...
Samsung Looks Beyond Biosimilars Via Takeda Tie-Up
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.